LL-37 (Cathelicidin) vs Thymosin Alpha-1

A detailed comparison to help you understand the differences and choose the right peptide for your research goals.

LL-37 (Cathelicidin)

LL-37 is the only human cathelicidin antimicrobial peptide. It plays crucial roles in innate immunity and has shown diverse biological activities including antimicrobial, immunomodulatory, and wound healing properties.

Full details →

Thymosin Alpha-1

Thymosin Alpha-1 is a peptide naturally produced by the thymus gland that plays a crucial role in immune system modulation. It is approved in over 35 countries for various conditions including hepatitis B and C.

Full details →

Side-by-Side Comparison

AspectLL-37 (Cathelicidin)Thymosin Alpha-1
MechanismDisrupts bacterial membranes, neutralizes endotoxins, modulates immune cell function, and promotes wound healing. Has both direct antimicrobial and immunomodulatory effects.Enhances T-cell function and maturation, stimulates dendritic cell activity, and modulates cytokine production. Promotes the differentiation of stem cells into mature T lymphocytes.
Typical DosageResearch protocols vary widely. Typical ranges: 50-200mcg administered subcutaneously 2-3 times weekly. Some protocols use higher doses for acute infections.Clinical dosing typically ranges from 1.6mg to 6.4mg administered subcutaneously 2-3 times weekly. Research protocols may vary.
AdministrationSubcutaneous injection. Can cause significant injection site reactions. Often used in conjunction with other immune-supporting protocols.Subcutaneous injection. Often used in cycles or as part of comprehensive immune support protocols.
Side EffectsInjection site pain and reactions are common. May cause flu-like symptoms, temporary fatigue, or immune activation responses.Generally well-tolerated. Rare side effects include injection site reactions, mild flu-like symptoms, and temporary fatigue.
Best For

What They Have in Common

Both LL-37 (Cathelicidin) and Thymosin Alpha-1 are commonly used for:

Ready to Learn More?